Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome

Osterweil, Emily K., Chuang, Shih-Chieh, Chubykin, Alexander A., Sidorov, Michael, Bianchi, Riccardo, Wong, Robert K.S., Bear, Mark F.·2013·Neuron
DOI 10.1016/j.neuron.2012.01.034

Cited by (230)

Items 101–200 of 230

  1. Elevated de novo protein synthesis in FMRP-deficient human neurons and its correction by metformin treatment
    Kagistia Hana Utami, Nur Amirah Binte Mohammad Yusof, Jing Eugene Kwa, Ulla‐Kaisa Peteri, Maija L. Castrén, Mahmoud A. Pouladi · 2020 · Molecular Autism
  2. Excessive proteostasis contributes to pathology in fragile X syndrome
    Susana R. Louros, Sang S. Seo, Beatriz Maio, Cristina Martinez‐Gonzalez, Miguel A. Gonzalez‐Lozano, Melania Muscas, Nick C. Verity, Jimi C. Wills, Ka Wan Li, Matthew F. Nolan et al. · 2022 · Neuron
  3. Pharmacotherapy for Fragile X Syndrome: Progress to Date
    Matthew H. Davenport, Tori L. Schaefer, Katherine Friedmann, Sarah E. Fitzpatrick, Craig A. Erickson · 2016 · Drugs
  4. Molecular mechanisms for targeted ASD treatments
    Bernadette Basilico, Jasmin Morandell, Gaia Novarino · 2020 · Current Opinion in Genetics & Development
  5. Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments
    María Jimena Salcedo‐Arellano, Ana Maria Cabal-Herrera, Ruchi Punatar, Courtney Jessica Clark, Christopher Allen Romney, Randi Jenssen Hagerman · 2020 · Neurotherapeutics
  6. Reversal of activity‐mediated spine dynamics and learning impairment in a mouse model of <scp>F</scp>ragile <scp>X</scp> syndrome
    Boda, Bernadett, Mendez, Pablo, Boury‐Jamot, Benjamin, Magara, Fulvio, Muller, Dominique · 2014 · European Journal of Neuroscience
  7. Lovastatin, Not Simvastatin, Corrects Core Phenotypes in the Fragile X Mouse Model
    Muscas, Melania, Louros, Susana R., Osterweil, Emily K. · 2019 · eneuro
  8. The Effect of Statins in Epilepsy: A Systematic Review
    Loraine De Jesús Quintana-Pájaro, Yancarlos Ramos-Villegas, Eileen Jhoana Cortecero-Sabalza, Andrei Fernandes Joaquim, Amit Agrawal, Alexis Rafael Narvaez‐Rojas, Luis Rafael Moscote‐Salazar · 2018 · Journal of Neurosciences in Rural Practice
  9. In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome
    Tiantian Wang, Laura G C de Kok, Rob Willemsen, Ype Elgersma, J. Gerard G. Borst · 2015 · Frontiers in Cellular Neuroscience
  10. A TrkB agonist and ampakine rescue synaptic plasticity and multiple forms of memory in a mouse model of intellectual disability
    Ronald R. Seese, Aliza A. Le, Kathleen Wang, Conor D. Cox, GARY S. LYNCH, Christine M. Gall · 2019 · Neurobiology of Disease
  11. Quantitative Profiling of Brain Lipid Raft Proteome in a Mouse Model of Fragile X Syndrome
    Kalinowska, Magdalena, Castillo, Catherine, Francesconi, Anna · 2015 · PLOS ONE
  12. Cell-type-specific disruption of cortico-striatal circuitry drives repetitive patterns of behavior in fragile X syndrome model mice
    Francesco Longo, Sameer Aryal, Paul G. Anastasiades, Marta Maltese, Corey Baimel, Federica Albanese, Joanna Tabor, Jeffrey D. Zhu, Mauricio Martins Oliveira, Denise Gastaldo et al. · 2023 · Cell Reports
  13. Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes
    Hansen Wang, Sandipan Bankim Behari Pati, Lucas D. Pozzo‐Miller, Laurie C. Doering · 2015 · Frontiers in Cellular Neuroscience
  14. Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model
    Leeyup Chung, Alexandra L. Bey, Aaron J. Towers, Xinyu Cao, Il Hwan Kim, Yong-Hui Jiang · 2017 · Neurobiology of Disease
  15. Inhibition of the ERK1/2 Phosphorylation by Dextromethorphan Protects against Core Autistic Symptoms in VPA Induced Autistic Rats: In Silico and in Vivo Drug Repurposition Study
    Rubal Singla, Abhishek Mishra, Rupa Joshi, Rohit Kumar, Phulen Sarma, Amit Raj Sharma, Gurjeet Kaur, Alka Bhatia, Bikash Medhi · 2021 · ACS Chemical Neuroscience
  16. Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice
    Michael S. Sidorov, Dilja Krueger‐Burg, Matthew John Taylor, Eugenia Gisin, Emily K. Osterweil, Mark F. Bear · 2014 · Genes Brain & Behavior
  17. APP Causes Hyperexcitability in Fragile X Mice
    Cara J. Westmark, Shih-Chieh Chuang, Seth A. Hays, Mikolaj J. Filon, Brian C. Ray, Pamela R. Westmark, Jay R. Gibson, Kimberly M. Huber, Robert K. S. Wong · 2016 · Frontiers in Molecular Neuroscience
  18. Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson’s disease
    Yi Tan, Carmelo Sgobio, Thomas Arzberger, Felix Machleid, Qilin Tang, Elisabeth Findeis, Jörg Tost, Tasnim Chakroun, Pan Gao, Mathias Höllerhage et al. · 2019 · Acta Neuropathologica
  19. Fragile X mental retardation protein: from autism to neurodegenerative disease
    Hansen Wang · 2015 · Frontiers in Cellular Neuroscience
  20. Dysregulated translational control in brain disorders: from genes to behavior
    Shane A. Wiebe, Anmol Nagpal, Nahum Sonenberg · 2020 · Current Opinion in Genetics & Development
  21. Experience-dependent weakening of callosal synaptic connections in the absence of postsynaptic FMRP
    Zhe Zhang, Jay R. Gibson, Kimberly M. Huber · 2021 · eLife
  22. An “Omic” Overview of Fragile X Syndrome
    Olivier Dionne, François Corbin · 2021 · Biology
  23. Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
    Aarti Tiwari, Saloni Rahi, Sidharth Mehan · 2020 · Current Drug Targets
  24. Cholesterol metabolism and Rett syndrome pathogenesis
    Nagy, Gabor, Ackerman, Susan L · 2013 · Nature Genetics
  25. Deletion of Long Isoform of Eukaryotic Elongation Factor 1Bδ Leads to Audiogenic Seizures and Aversive Stimulus-Induced Long-Lasting Activity Suppression in Mice
    Taku Kaitsuka, Hiroshi Kiyonari, Aki Shiraishi, Kazuhito Tomizawa, Masayuki Matsushita · 2018 · Frontiers in Molecular Neuroscience
  26. Regional rates of brain protein synthesis are unaltered in dexmedetomidine sedated young men with fragile X syndrome: A L-[1-11C]leucine PET study
    Kathleen Schmidt, Inna Loutaev, Zenaide Quezado, Carrie A. Sheeler, Carolyn Beebe Smith · 2020 · Neurobiology of Disease
  27. Dysregulation of translational control signaling in autism spectrum disorders
    Mehdi Hooshmandi, Calvin Wong, Arkady Khoutorsky · 2020 · Cellular Signalling
  28. Transcriptome signature analysis repurposes trifluoperazine for the treatment of fragile X syndrome in mouse model
    Qi Ding, Ferzin Sethna, Xueting Wu, Zhuang Miao, Ping Chen, Yueqi Zhang, Hua Xiao, Wei Feng, Yue Feng, Xuan Li et al. · 2020 · Communications Biology
  29. Drug-responsive autism phenotypes in the 16p11.2 deletion mouse model: a central role for gene-environment interactions
    Emma J. Mitchell, David M. Thomson, Rebecca L. Openshaw, Greg C. Bristow, Neil Dawson, Judith A. Pratt, BRIAN J. MORRIS · 2020 · Scientific Reports
  30. Simvastatin Restores HDAC1/2 Activity and Improves Behavioral Deficits in Angelman Syndrome Model Mouse
    Vipendra Kumar, Tripti Joshi, Naman Vatsa, Brijesh Kumar Singh, Nihar Ranjan Jana · 2019 · Frontiers in Molecular Neuroscience
  31. FMRP binding to a ranked subset of long genes is revealed by coupled CLIP and TRAP in specific neuronal cell types
    Sarah J. Van Driesche, Kirsty Sawicka, Chaolin Zhang, Ka Ying Sharon Hung, Christopher Y. Park, John J. Fak, Chingwen Yang, Robert B. Darnell, Jennifer C. Darnell · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  32. Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial
    Champigny, Camille, Morin-Parent, Florence, Bellehumeur-Lefebvre, Laurence, Çaku, Artuela, Lepage, Jean-François, Corbin, François · 2022 · Frontiers in Psychiatry
  33. Convergent synaptic and circuit substrates underlying autism genetic risks
    Aaron W. McGee, Guohui Li, Zhongming Lu, Shenfeng Qiu · 2014 · Frontiers in Biology
  34. Translational endpoints in fragile X syndrome
    Celine E. F. de Esch, Shimriet Zeidler, Rob Willemsen · 2013 · Neuroscience & Biobehavioral Reviews
  35. A Highly Selective MNK Inhibitor Rescues Deficits Associated with Fragile X Syndrome in Mice
    Tarjani N. Shukla, June Bryan de la Peña, John M. Perish, Jonathan E. Ploski, Craig R. Stumpf, Kevin R. Webster, Catherine A. Thorn, Zachary T. Campbell · 2020 · Neurotherapeutics
  36. Mechanisms regulating input-output function and plasticity of neurons in the absence of FMRP
    Sam A. Booker, Peter C. Kind · 2021 · Brain Research Bulletin
  37. New Therapeutic Options for Fragile X Syndrome
    Isha R. Jalnapurkar, David Cochran, Jean A. Frazier · 2019 · Current Treatment Options in Neurology
  38. Myelination Deficits in the Auditory Brainstem of a Mouse Model of Fragile X Syndrome
    Alexandra Lucas, Shani Poleg, Achim Klug, E. McCullagh · 2021 · bioRxiv
  39. Phenotypic variability to medication management: an update on fragile X syndrome
    Nasser Attia Elhawary, Imad A. AlJahdali, Iman Sabri Abumansour, Zohor Asaad Azher, Alaa Hisham Falemban, Wefaq M. Madani, Wafaa Alosaimi, Ghydda Alghamdi, Ikhlas A. Sindi · 2023 · Human Genomics
  40. Targeted treatments in fragile X syndrome
    Emma B. Hare, Randi Jenssen Hagerman, Reymundo Lozano · 2014 · Expert Opinion on Orphan Drugs
  41. ß-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X
    Benjamin D. Auerbach, Robert J. Lefkowitz, Laura J. Stoppel, Rebecca K. Senter, Anthony R. Preza, Mark F. Bear · 2017 · DSpace@MIT (Massachusetts Institute of Technology)
  42. Cholesterol metabolism pathway in autism spectrum disorder: From animal models to clinical observations
    Jaime Hui Xian Lin, Victória Linden de Rezende, Maiara de Aguiar da Costa, Jade de Oliveira, Cinara Ludvig Gonçalves · 2023 · Pharmacology Biochemistry and Behavior
  43. Caveolin-1-Mediated Cholesterol Accumulation Contributes to Exaggerated mGluR-Dependent Long-Term Depression and Impaired Cognition in Fmr1 Knockout Mice
    Li Luo, Le Yang, Kun Zhang, Shimeng Zhou, Yan Wang, Liu-kun Yang, Bin Feng, Shui‐bing Liu, Yumei Wu, Ming Zhao et al. · 2023 · Molecular Neurobiology
  44. The Ins and Outs of miRNA-Mediated Gene Silencing during Neuronal Synaptic Plasticity
    Dipen Rajgor, Jonathan G. Hanley · 2016 · Non-Coding RNA
  45. Female-specific dysfunction of sensory neocortical circuits in a mouse model of autism mediated by mGluR5 and estrogen receptor α
    Gemma Molinaro, Jacob E. Bowles, Katilynne Croom, Darya Gonzalez, Saba Mirjafary, Shari G. Birnbaum, Khaleel A. Razak, Jay R. Gibson, Kimberly M. Huber · 2024 · Cell Reports
  46. Screening and genetic engineering of marine-derived Aspergillus terreus for high-efficient production of lovastatin
    Han Na, Yao‐Yao Zheng, Yaoning Jia, Jingzhao Feng, Jizi Huang, Jihao Huang, Chang‐Yun Wang, Guangshan Yao · 2024 · Microbial Cell Factories
  47. Non-ionotropic signaling through the NMDA receptor GluN2B carboxy-terminal domain drives dendritic spine plasticity and reverses fragile X phenotypes
    Stephanie A. Barnes, Aurore Thomazeau, Peter S.B. Finnie, Maxwell J. Heinrich, Arnold J. Heynen, Noboru H. Komiyama, Seth G. N. Grant, Frank S. Menniti, Emily K. Osterweil, Mark F. Bear · 2025 · Cell Reports
  48. Rates of protein synthesis are reduced in peripheral blood mononuclear cells (PBMCs) from fragile X individuals
    Olivier Dionne, Audrey Lortie, Florence Gagnon, François Corbin · 2021 · PLoS ONE
  49. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
    Ramkumar Aishworiya, Tatiana Valica, Randi Jenssen Hagerman, Bibiana Restrepo · 2024 · FOCUS The Journal of Lifelong Learning in Psychiatry
  50. Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon
    Randi Jenssen Hagerman, Paul J. Hagerman · 2021 · The Annual Review of Pharmacology and Toxicology
  51. Modelling Protein Synthesis as A Biomarker in Fragile X Syndrome Patient-Derived Cells
    Rakhi Pal, Aditi Bhattacharya · 2019 · Brain Sciences
  52. Brain Cholesterol Biosynthetic Pathway Is Altered in a Preclinical Model of Fragile X Syndrome
    Parente, Martina, Tonini, Claudia, Buzzelli, Valeria, Carbone, Emilia, Trezza, Viviana, Pallottini, Valentina · 2022 · International Journal of Molecular Sciences
  53. FMRP deficiency leads to multifactorial dysregulation of splicing and mislocalization of MBNL1 to the cytoplasm
    Suna Jung, Sneha Shah, Geongoo Han, Joel D. Richter · 2023 · PLoS Biology
  54. Intellectual Disabilities and Global Developmental Delay
    Elana F. Pinchefsky, Michael Israel Shevell · 2017 · Springer eBooks
  55. Vorinostat Corrects Cognitive and Non-Cognitive Symptoms in a Mouse Model of Fragile X Syndrome
    Qi Ding, Xueting Wu, Xuan Li, Hongbing Wang · 2021 · The International Journal of Neuropsychopharmacology
  56. Fragile X syndrome: clinical presentation, pathology and treatment
    Ma. Jimena Salcedo-Arellano, Randi J. Hagerman, Verónica Martínez-Cerdeño · 2020 · Gaceta Médica de México
  57. The mGluR Theory of Fragile X: From Mice to Men
    Laura J. Stoppel, Emily K. Osterweil, Mark F. Bear · 2017 · Elsevier eBooks
  58. Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism
    Craig A. Erickson, Balmiki Ray, Logan K. Wink, Baindu L. Bayon, Ernest V. Pedapati, Rebecca C. Shaffer, Tori L. Schaefer, Debomoy K. Lahiri · 2016 · Journal of Psychiatric Research
  59. Fragile X Syndrome and Targeted Treatments
    Nattaporn Tassanakijpanich, Ana Maria Cabal-Herrera, María Jimena Salcedo‐Arellano, Randi Jenssen Hagerman · 2020 · Journal of Biomedicine and Translational Research
  60. Considerations for Clinical Therapeutic Development of Statins for Neurodevelopmental Disorders
    Myrthe J. Ottenhoff, Lianne C. Krab, Ype Elgersma · 2020 · eNeuro
  61. Glucose and lipid metabolism screening models of hepatocyte spheroids after culture with injectable fiber fragments
    Jiaojun Wei, Tian Xia, Weijia Chen, Pan Ran, Maohua Chen, Xiaohong Li · 2020 · Journal of Tissue Engineering and Regenerative Medicine
  62. An iPSC-derived astrocyte model of fragile X syndrome exhibits dysregulated cholesterol homeostasis
    Talvio, Karo, Wagner, Victoria A., Minkeviciene, Rimante, Kirkwood, Jay S., Kulinich, Anna O., Umemori, Juzoh, Bhatia, Anil, Hur, Manhoi, Käkelä, Reijo, Ethell, Iryna M. et al. · 2023 · Communications Biology
  63. Astrocytes in fragile X syndrome
    Talvio, Karo, Castrén, Maija L. · 2024 · Frontiers in Cellular Neuroscience
  64. A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder
    Sushmitha S. Purushotham, Neeharika M. N. Reddy, Michelle Ninochka D’Souza, Nilpawan Roy Choudhury, Anusa Ganguly, Niharika Gopalakrishna, Ravi Sondekoppa Muddashetty, James Premdoss Clement · 2022 · Experimental Brain Research
  65. Developing BACE-1 inhibitors for FXS
    Cara J. Westmark, Elizabeth Berry‐Kravis, Chrysanthy Ikonomidou, Jerry C. P. Yin, Luigi Puglielli · 2013 · Frontiers in Cellular Neuroscience
  66. Calcium-Dependent Regulation of Neuronal Excitability Is Rescued in Fragile X Syndrome by a Tat-Conjugated N-Terminal Fragment of FMRP
    Xiaoqin Zhan, Hadhimulya Asmara, Paul J. Pfaffinger, Ray W. Turner · 2024 · Journal of Neuroscience
  67. Fragile X Mental Retardation Protein Restricts Small Dye Iontophoresis Entry into Central Neurons
    Tyler Kennedy, Kendal S. Broadie · 2017 · Journal of Neuroscience
  68. Effects of the presence and absence of amino acids on translation, signaling, and long‐term depression in hippocampal slices from Fmr1 knockout mice
    Spencer K. Cooke, Jacob Russin, Kristen Moulton, Jeffrey Nadel, Inna Loutaev, Qinhua Gu, Zheng Li, Carolyn Beebe Smith · 2019 · Journal of Neurochemistry
  69. Effect of acute and chronic exposure to lovastatin on the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model
    Michał Tomaszewski, Dorota Żółkowska, Zbigniew Plewa, Stanisław Jerzy Czuczwar, Jarogniew Jacek Łuszczki · 2021 · European Journal of Pharmacology
  70. A Farnesyltransferase Inhibitor Restores Cognitive Deficits inTsc2+/–Mice through Inhibition of Rheb1
    Hiroko Sugiura, Tadayuki Shimada, Keiko Moriya‐Ito, Jun-Ichi Goto, Hiroki Fujiwara, Rie Ishii, Hiroshi Shitara, Choji Taya, Satoshi Fujii, Toshiyuki Kobayashi et al. · 2022 · Journal of Neuroscience
  71. Pirenperone relieves the symptoms of fragile X syndrome in Fmr1 knockout mice
    Yujeong Kim, Se Jin Jeon, Edson Luck Gonzales, Dongpil Shin, Chilly Gay Remonde, TaeJin Ahn, Chan Young Shin · 2022 · Scientific Reports
  72. Fragile X Syndrome Therapeutics: Translation, Meet Translational Medicine
    Jonathan O. Lipton, Mustafa Şahin · 2013 · Neuron
  73. Lymphocytic Extracellular Signal–Regulated Kinase Dysregulation in Autism Spectrum Disorder
    Craig A. Erickson, Charles R. Tessier, Christina Groß, Ernest V. Pedapati, Logan K. Wink, Kelli C. Dominick, Rebecca C. Shaffer, Hilary Rosselot, Michael P. Hong, Andrew P. Bantel et al. · 2023 · Journal of the American Academy of Child & Adolescent Psychiatry
  74. A Differential Effect of Lovastatin versus Simvastatin in Neurodevelopmental Disorders
    Melania Muscas, Sang S. Seo, Susana R. Louros, Emily K. Osterweil · 2020 · eNeuro
  75. The Use of Peptides in the Treatment of Fragile X Syndrome: Challenges and Opportunities
    Alice Romagnoli, Daniele Di Marino · 2021 · Frontiers in Psychiatry
  76. The cleavage of host cell proteins by HIV-1 protease.
    Václav Snåšel, I. (Iva) Pichová · 1996 · PubMed
  77. Neurophysiological effects of a combined treatment of lovastatin and minocycline in patients with fragile X syndrome: Ancillary results of the LOVAMIX randomized clinical trial
    Florence Morin‐Parent, Camille M. Champigny, Samantha Rae Cote, Teddy Mohamad, Seyede Anis Hasani, Artuela Çaku, François Corbin, Jean‐François Lepage · 2024 · Autism Research
  78. Results from a Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Trial of Lovastatin or Minocycline in Fragile X Syndrome
    Walker S. McKinney, Lauren Schmitt, Lisa A. De Stefano, Lauren E. Ethridge, Jordan E. Norris, Paul S. Horn, Shelby Dauterman, Hilary Rosselot, Ernest V. Pedapati, Debra L. Reisinger et al. · 2024 · Journal of Child and Adolescent Psychopharmacology
  79. Identification of a male with fragile X syndrome through newborn screening
    Jessica Famula, Kirin Basuta, Louise W. Gane, Randi Jenssen Hagerman, Flora Tassone · 2015 · Intractable & Rare Diseases Research
  80. Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome
    Kaizad R. Munshi, Katherine G. Pawlowski, Joseph Gonzalez–Heydrich, Jonathan D. Picker · 2017 · Journal of Child and Adolescent Psychopharmacology
  81. Family and Caregiver Characteristics Contribute to Caregiver Change in Use of Strategies and Growth in Child Spoken Language in a Parent-Implemented Language Intervention in Fragile X Syndrome
    Sarah Nelson Potter, Lauren Bullard, Amy Banasik, Robyn Tempero Feigles, Vivian H. Nguyen, Andrea S. McDuffie, Angela John Thurman, Randi Jenssen Hagerman, Leonard Abbeduto · 2022 · Perspectives of the ASHA Special Interest Groups
  82. Crosstalk between ubiquitination and translation in neurodevelopmental disorders
    Nagore Elu, Srividya Subash, Susana R. Louros · 2024 · Frontiers in Molecular Neuroscience
  83. Evaluation of Rett Syndrome Symptom Improvement by Metabolic Modulators in Mecp2‐Mutant Mice
    Christie M. Buchovecky, Misty Hill, Jennifer M. Borkey, Stephanie M. Kyle, Monica J. Justice · 2013 · Current Protocols in Mouse Biology
  84. Hyperactivation of MEK1 in cortical glutamatergic neurons results in projection axon deficits and aberrant motor learning
    George R. Bjorklund, Katherina P. Rees, Kavya Balasubramanian, Lauren T. Hewitt, Kenji J. Nishimura, Jason M. Newbern · 2024 · Disease Models & Mechanisms
  85. Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction
    Michael Telias · 2019 · Current Pharmaceutical Design
  86. SRC family kinase inhibition rescues molecular and behavioral phenotypes, but not protein interaction network dynamics, in a mouse model of Fragile X syndrome
    Vera Stamenković, Jonathan D. Lautz, Felicia M. Harsh, Stephen E.P. Smith · 2024 · Molecular Psychiatry
  87. Contribution of astrocytic calcium signaling to auditory hypersensitivity in a mouse model of fragile X syndrome
    Lara Bergdolt, Alexandria Anding, Ola Alshaqi, Zahra Arbabi, Michael Douchey, Ember Eldridge, Katherine Hoffman, Ashley Reid, Kiran Sapkota, Daniel T. Monaghan et al. · 2026 · Neurobiology of Disease
  88. Growth-suppressor microRNAs mediate synaptic overgrowth and behavioral deficits in Fragile X mental retardation protein deficiency
    Megha P. Subramanian, William T. Mills, Manish D. Paranjpe, Uche S Onuchukwu, Manasi Inamdar, Amanda R Maytin, Xinbei Li, Joel L. Pomerantz, Mollie K. Meffert · 2023 · iScience
  89. Behavioural difficulties in fragile X syndrome: current pharmacological options and potential future developments
    Andrew C. Stanfield, Andrew G. McKechanie · 2025 · Expert Review of Neurotherapeutics
  90. Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome
    Sebastian Scharf, F. Gasparini, W. Spooren, L. Lindemann · 2017 · Elsevier eBooks
  91. mTOR signaling in proteostasis and its relevance to autism spectrum disorders
    Judit Faus-Garriga, 1 Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, 08003, Barcelona, Spain, Isabel Novoa, Andrés Ozaita · 2017 · AIMS Biophysics
  92. Intracellular Signaling Networks in Fragile X Syndrome: Approaches to Drug Discovery and Therapeutics
    Christina Groß, Aditi Bhattacharya · 2017 · Elsevier eBooks
  93. Pioglitazone improves deficits of Fmr1 -KO mouse model of Fragile X syndrome by interfering with excessive diacylglycerol signaling
    Andréa Geoffroy, Karima Habbas, Boglárka Zámbó, Laetitia Schramm, Arnaud Duchon, Eric Flatter, Laëtitia Fouillen, Julie Zumsteg, Dimitri Heintz, Jean‐Louis Mandel et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  94. Cell type-specific disruption of cortico-striatal circuitry drives repetitive patterns of behaviour in fragile X syndrome model mice
    Francesco Longo, Sameer Aryal, Paul G. Anastasiades, Marta Maltese, Corey Baimel, Federica Albanese, Joanna Tabor, Jeffrey D. Zhu, Mauricio Martins Oliveira, Denise Gastaldo et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  95. Novel presynaptic assay system revealed that metformin ameliorates exaggerated synaptic release and Munc18-1 accumulation in presynapses of neurons from Fragile X syndrome mouse model
    Renoma Takeda, Rie Ishii, Shumaia Parvin, Aki Shiozawa, Terukazu Nogi, Yukio Sasaki · 2023 · Neuroscience Letters
  96. Therapeutic approaches for the future treatment of Fragile X
    Ana Sastre, Nuria Eugenia Campillo, Carmen Gil, Ana Martı́nez · 2015 · Current Opinion in Behavioral Sciences
  97. Enhanced CB1 receptor function in GABAergic neurons mediates hyperexcitability and impaired sensory-driven synchrony of cortical circuits in Fragile X Syndrome model mice
    D. Gonzalez, CR Jonak, Matteo Bernabucci, Gemma Molinaro, K. Collins, SA Assad, Jay R. Gibson, Devin K. Binder, Kimberly M. Huber · 2025 · Molecular Psychiatry
  98. mRNA Translation and Proteasomal Degradation in Health and Neurological Disease
    Alinny Rosendo Isaac, Danielle Cozachenco, Beatriz de A Wagner, Mariana Gomes Chauvet, Mychael V. Lourenco · 2026 · Physiology
  99. A microglial basis for fragile X syndrome via impairment of FMRP-regulated lysosomal function
    Heng Li, Jennifer Ja-Yoon Choi, Eric Jinsheng Huang, Baoji Xu · 2026 · Molecular Psychiatry
  100. Epigenetic causes of intellectual disability—the fragile X syndrome paradigm
    Elisabetta Tabolacci, Giovanni Neri · 2016 · Elsevier eBooks